D-Dimer as Predictor of Disease Outcome in Intensive Care Unit in COVID-19m Patients

D-Dimer as Predictor of Disease Outcome in Intensive Care Unit in SARS-COV-2 Patients: A Retrospective Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05279469

Acronym

COVID-19

Enrollment

465

Registered

2022-03-15

Start date

2021-06-10

Completion date

2022-03-09

Last updated

2022-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical Illness, Pneumonia, Viral

Keywords

D dimer, SARS-COV-2

Brief summary

Evaluating value of D-Dimer blood level of icu admitted patients on admission and 48 hours later as outcome predictor in SARS.COV.2 patients.

Detailed description

Evaluating value of D-Dimer blood level of icu admitted patients on admission and 48 hours later as outcome predictor in SARS.COV.2 patients. It has been reported that COVID 19 is associated with hemostatic abnormalities and elevated D-Dimer level, so its level is used to predict severity of disease.

Interventions

OTHERno intervention, just observational for D-Dimer level in blood

observation for basal D-Dimer and 48 hours later D-Dimer in blood for ICU SARS.COV.2 patients

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* patients of both sex admitted in icu * positive PCR * requiring oxygen therapy

Exclusion criteria

* ward patients * negative PCR

Design outcomes

Primary

Measure	Time frame	Description
28 days mortality	1 month	Outcomes of ICU stay

Secondary

Measure	Time frame	Description
length of stay and mechanical ventilation	during ICU stay	time of admission and need to escalate oxygen therapy

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026